News: Simtuzumab

We provide the latest news and info on Simtuzumab


Bidness ETC
Gilead Down on Weak Simtuzumab Data and Sovaldi News
Zacks.com
Gilead however is evaluating simtuzumab in other indications such as advanced colorectal cancer, myelofibrosis, idiopathic pulmonary fibrosis and liver fibrosis caused by non-alcoholic steatohepatitis and primary sclerosing cholangitis. Similar ...
Gilead's simtuzumab fails in Ph II pancreatic cancer studyThe Pharma Letter
Gilead reports Phase 2 trial results Of Simtuzumab For Pancreatic CancerRTT News
Gilead Announces Data From Phase 2 Study of Simtuzumab for Previously ...Fort Mills Times
Drug Discovery & Development -Jutia Group -Barron's (blog)
all 45 news articles »

Published on Monday 20th of October 2014 02:21:46 AM Read more...

For advanced pancreatic cancer, simtuzumab not significantly more effective ...
Oncology Nurse Advisor
Gilead Sciences, Inc. has announced results from their phase 2 trial studying simtuzumab plus gemcitabine for the treatment of patients with previously untreated advanced pancreatic cancer. Researchers found that patients who received gemcitabine in ...

Published on Monday 20th of October 2014 02:21:46 AM Read more...

Gilead anuncia datos del estudio de Fase 2 de simtuzumab para pacientes con ...
Lainformacion.com
Gilead Sciences, Inc. (Nasdaq:GILD) ha anunciado los resultados de un estudio de Fase 2 que evalúa simtuzumab, un inhibidor de la lisil oxidasa-tipo-2 (LOXL2), en combinación con gemcitabina para pacientes con cáncer de páncreas avanzado no tratado ...

and more »

Published on Monday 20th of October 2014 02:21:46 AM Read more...


Drug Discovery & Development
Reversing Idiopathic Pulmonary Fibrosis
Drug Discovery & Development
Two more interesting drugs, Hogaboam said, are Gilead's Simtuzumab (targeting LoxL2) and Biogen Idec's STX-100 (targeting alpha-beta-6 integrin), both in Phase 2 trial. And high-resolution CT scans will bring earlier diagnosis, key as fibrosis is more ...

and more »

Published on Monday 20th of October 2014 02:21:46 AM Read more...

Gilead gibt Daten von Phase-2-Studie von Simtuzumab bei nicht ...
OnVista
Gilead Sciences, Inc. (Nasdaq:GILD) hat heute die Ergebnisse einer Phase-2-Studie zur Bewertung von Simtuzumab bekannt gegeben, einem Prüfpräparat zur Hemmung von Lysyloxidase-Like-2 (LOXL2), in Kombination mit Gemcitabin für Patienten mit ...

and more »

Published on Monday 20th of October 2014 02:21:46 AM Read more...

Our Services

Do not forget to check the lastest products and auctions related to Simtuzumab as well as our free videos and podcasts.

best Simtuzumab products current Simtuzumab auctions current Simtuzumab videos listen to Simtuzumab podcasts